What does Vigonvita Life Sciences do?

Vigonvita is a Suzhou-based drug developer that discovers and tests new pill-type (small molecule) medicines. Its pipeline targets depression, schizophrenia, epilepsy, erectile dysfunction, premature ejaculation, and viral infections such as RSV, COVID-19 and influenza. Most candidates are still in clinical trials.

Healthcare · Drug Manufacturers - General · 2630.HK

What Vigonvita Life Sciences Does & How It Makes Money (2630.HK)

Updated October 2026 · reflects Vigonvita Life Sciences's latest reported financials

Chinese biotech developing small-molecule drugs for brain, sexual health, viruses. It aims to earn revenue by bringing its drug candidates to market after regulatory approval.

Vigonvita Life Sciences's story, moat and numbers — in a 3-minute visual book.

Explore Vigonvita Life Sciences on TacticScale →

How Vigonvita Life Sciences makes money

It aims to earn revenue by bringing its drug candidates to market after regulatory approval. With most products still in trials, value depends on clinical success and commercialization.

What Vigonvita Life Sciences does

Vigonvita Life Sciences is a clinical-stage Chinese biopharmaceutical company, founded in 2013 and headquartered in Suzhou, focused on discovering, developing and commercializing small molecule drugs in three areas: neuropsychiatry, reproductive health and viral infections. Its most advanced assets include TPN171, a PDE5 inhibitor for erectile dysfunction that has completed Phase III, and VV116, an RNA polymerase inhibitor that has completed Phase II for RSV and is also being developed for COVID-19. The pipeline also includes LV232, a first-in-class dual-target antidepressant in Phase II; early-stage candidates for epilepsy (TPN102), schizophrenia (VV119) and broad-spectrum viral infections (VV261); and preclinical-stage programs for premature ejaculation, major depressive disorder and adenovirus infection.

Products & services

LV232 (depression, Phase II)
TPN171 (erectile dysfunction, Phase III completed)
VV116 (RSV/COVID-19 antiviral)
TPN102 (epilepsy, Phase I)
VV119 (schizophrenia, Phase I)
VV261 (broad-spectrum antiviral, Phase I)

What is Vigonvita Life Sciences worth?

Fair value: not published

A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.

We show a fair value only when the method is trustworthy. See Vigonvita Life Sciences on TacticScale →

Sector Healthcare Industry Drug Manufacturers - General HQ China Ticker 2630.HK Official site

Related companies

Livzon Pharmaceutical (000513.SZ) · Viatris (VTRS) · Vir Biotechnology (VIR) · InventisBio (688382.SS)

Understand Vigonvita Life Sciences in 3 minutes →